Spero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022

Rhea-AI Summary

Spero Therapeutics (Nasdaq: SPRO) has announced a conference call on August 10, 2022, at 4:30 p.m. ET to discuss its Q2 2022 financial results and update its business operations and pipeline. Investors can access the call via phone or through a live audio webcast available on Spero's website. The archived webcast will be available for 30 days post-call. Spero is focused on developing treatments for bacterial infections, including multi-drug resistant strains, with pipeline candidates including SPR720, SPR206, and investigational drug Tebipenem HBr.

Positive

• Spero is hosting a call to discuss its Q2 2022 financials, indicating transparency with investors.
• The focus on developing treatments for multi-drug resistant infections positions Spero in a critical market.
• Pipeline candidates like SPR720 and SPR206 cater to unmet medical needs.

Negative

• None.

CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Wednesday, August 10, 2022 at 4:30 p.m. ET to report its second quarter 2022 financial results and provide an update on its business and pipeline.

To access the call, please dial 1-877-704-4453 (domestic) or 1-201-389-0920 (international) and refer to conference ID 13731565. The audio webcast can be accessed under “Events and Presentations” in the Investor and Media section of the Company’s website at www.sperotherapeutics.com. The archived webcast will also be available on Spero’s website for 30 days following the call.

About Spero Therapeutics
Spero Therapeutics is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for bacterial infections, including multi-drug resistant bacterial infections and rare diseases.

• Spero Therapeutics is developing SPR720 as a novel oral therapy candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections.
   
• Spero Therapeutics also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is in development to treat multi-drug resistant Gram-negative infections in the hospital setting.

• Tebipenem HBr is an investigational drug in the United States being developed for the treatment of cUTI, including pyelonephritis, caused by certain microorganisms, in adult patients who have limited treatment options; tebipenem HBr is not FDA-approved.
  

For more information, visit https://sperotherapeutics.com.

Investor Relations Contact: 
Ted Jenkins
Vice President, Investor Relations and Strategic Finance
TJenkins@sperotherapeutics.com
(617) 798-4039

Media Inquiries: media@sperotherapeutics.com

FAQ

What will Spero Therapeutics discuss in its August 10, 2022 call?

Spero Therapeutics will discuss its Q2 2022 financial results and provide updates on its business operations and pipeline.

How can I access the Spero Therapeutics conference call?

The call can be accessed by dialing 1-877-704-4453 for domestic calls or 1-201-389-0920 for international calls. A live audio webcast is also available on Spero's website.

What is the focus of Spero Therapeutics?

Spero Therapeutics focuses on developing treatments for bacterial infections, including multi-drug resistant infections and rare diseases.

What are the key products in Spero's pipeline?

Key products include SPR720, a treatment for rare pulmonary diseases, SPR206 for multi-drug resistant Gram-negative infections, and the investigational drug Tebipenem HBr for cUTI.